Pharma giants' oral EPO alternatives could cater to dopers

GlaxoSmithKline CEO Andrew Witty has high hopes for an experimental pill his company is developing for anemia, as the drug could offer an oral alternative to injected EPO therapies. Japanese drugmaker Astellas and other outfits stand to gain from …
See all stories on this topic »